Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy
Journal Article
·
· Journal of Clinical Investigation
- Massachusetts General Hospital, Boston, MA (United States)
- National Institute of Environmental Health Sciences, Research Triangle Park, NC (United States)
- InBio, Charlottesville, VA (United States)
- Harvard Univ., Cambridge, MA (United States)
- Univ. Paris-Saclay, Gif-sur-Yvette (France)
- Massachusetts Inst. of Technology (MIT), Cambridge, MA (United States). Koch Institute for Integrative Cancer Research
In IgE-mediated food allergies, exposure to the allergen activates systemic allergic responses. Oral immunotherapy (OIT) treats food allergies through incremental increases in oral allergen exposure. However, OIT only induces sustained clinical tolerance and decreased basophil sensitivity in a subset of individuals despite increases in circulating allergen-specific IgG in all treated individuals. Therefore, we examined the allergen-specific antibodies from 2 OIT cohorts of patients with sustained and transient responses. Here, we compared antibodies from individuals with sustained or transient responses and discovered specific tolerance-associated conformational epitopes of the immunodominant allergen Ara h 2 recognized by neutralizing antibodies. First, we identified what we believe to be previously unknown conformational, intrahelical epitopes using x-ray crystallography with recombinant antibodies. We then identified epitopes only recognized in sustained tolerance. Finally, antibodies recognizing tolerance-associated epitopes effectively neutralized allergen to suppress IgE-mediated effector cell activation. Our results demonstrate the molecular basis of antibody-mediated protection in IgE-mediated food allergy, by defining how these antibodies disrupt IgE-allergen interactions to prevent allergic reactions. Our approach to studying the structural and functional basis for neutralizing antibodies demonstrates the clinical relevance of specific antibody clones in antibody-mediated tolerance. We anticipate that our findings will form the foundation for treatments of peanut allergy using neutralizing antibodies and hypoallergens.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- USDOE Office of Science (SC), Basic Energy Sciences (BES)
- Grant/Contract Number:
- AC02-06CH11357
- OSTI ID:
- 2423466
- Journal Information:
- Journal of Clinical Investigation, Journal Name: Journal of Clinical Investigation Journal Issue: 2 Vol. 133; ISSN 1558-8238
- Publisher:
- American Society for Clinical InvestigationCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
Design of an Ara h 2 hypoallergen from conformational epitopes
T‐cell epitope‐containing hypoallergenic β‐lactoglobulin for oral immunotherapy in milk allergy
Journal Article
·
Wed Apr 11 20:00:00 EDT 2018
· Nature Communications
·
OSTI ID:1624085
Design of an Ara h 2 hypoallergen from conformational epitopes
Journal Article
·
Sun Dec 31 23:00:00 EST 2023
· Clinical & Experimental Allergy
·
OSTI ID:2582705
T‐cell epitope‐containing hypoallergenic β‐lactoglobulin for oral immunotherapy in milk allergy
Journal Article
·
Thu Sep 15 20:00:00 EDT 2016
· Pediatric Allergy and Immunology
·
OSTI ID:1401467